Allarity Signs First CLIA Laboratory Contract to Support European Oncology Treatment Prediction Device
Key Facts
On October 30, 2026, Allarity Therapeutics announced it had signed the first revenue-generating contract under its new strategy for CLIA-certified laboratory services, supporting a European biotechnology company developing a predictive device in precision oncology for use in the United States. The company said development and validation services will be provided for the project, expanding the commercial use of its Danish laboratory. The announcement described the agreement as the start of a potential path to additional recurring revenue, but did not disclose the contract's value or duration. The agreement's financial contribution therefore remains unspecified in the published information. The contract comes as Allarity says stenoparib remains its main development focus.
The agreement represents an external use of laboratory capabilities the company developed to support its clinical programs. In July, Allarity said its laboratory in Denmark could conduct DRP testing and additional laboratory services for companies seeking to run clinical trials in the United States or support products marketed there. The company's in-house laboratory in Hørsholm received CLIA registration, authorizing it to conduct DRP testing for U.S. studies, including a potential pivotal registration trial of stenoparib for advanced ovarian cancer. The company had said laboratory certification could reduce its reliance on outside laboratories, potentially shorten testing turnaround times and lower costs. These capabilities provide a foundation for services to partners, alongside their use in Allarity's own programs.
The company expanded the laboratory's scope before announcing the contract: in September, it added proteomics research and cell lines to transcriptomics research and CLIA-certified clinical testing services. It said the new protein panel measures approximately 300 protein targets. Chief Executive Thomas Jensen said the expanded capabilities enable the company to offer a broader range of scientific services to external partners. The development and validation contract adds a commercial application for this strategy, which makes use of existing laboratory equipment, according to the announcement summary. The company has not disclosed the value of the services or their implementation timeline in the available information.
The company's oncology-related services rely on DRP technology, which Allarity describes as a way to examine changes in gene expression in tumor tissue and estimate the likelihood that it will respond to a particular treatment. The company aims to use the test to select patients for a pivotal stenoparib trial and has said this approach is part of developing the drug toward U.S. Food and Drug Administration approval. In an exploratory analysis of patients with advanced ovarian cancer in a Phase 2 trial, the company linked higher pretreatment DRP scores with longer overall survival, saying the result supports the possibility of identifying patients who may achieve longer-lasting benefit. As presented by the company, these results remain a basis for developing the test's use, not an announcement of therapeutic approval. Allarity describes stenoparib as an oral small-molecule inhibitor targeting PARP1/2 and tankyrase 1/2, with potential development pathways in ovarian, small-cell lung, and colorectal cancers.
The expansion separates the external services business from the core drug program, the company emphasized. Allarity has said stenoparib remains its top development priority and that its experience developing response biomarkers for other drugs provides a basis for external partnerships. A separate Phase 2 trial evaluating stenoparib with temozolomide in patients with relapsed small-cell lung cancer had also begun enrolling patients in early 2026 and was receiving patients at several U.S. Department of Veterans Affairs sites. Financially, the company's cash and restricted cash totaled $26.9 million on June 30, 2026, compared with $14.7 million on the same date in 2025. That reflects a higher cash balance year over year, while the company has not disclosed the financial terms of the new contract.
In the market, shares of Allarity Therapeutics, which trade under the ticker ALLR, closed at $0.89 on October 29, 2026, after closing at $0.95 in the previous session. This coincided with the company's contract announcement, but closing-price data alone do not establish the news's effect on the stock's movement. The significance of the deal depends on the development of the partnership and the services the company will provide, while the agreement's value and duration have not been disclosed. Within the timeframe set by the company, using DRP to select patients for a pivotal stenoparib trial remains part of the development program toward FDA approval. External laboratory services remain a potential partnership and revenue opportunity, the company said.